UNSPSC 51373459: Codeine/pseudoephedrine/triprolidine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373459 Codeine/pseudoephedrine/triprolidine is a Commodity code that in recent state and local procurement covers pharmaceutical products used in correctional healthcare and community health initiatives, including parenteral nutrition solutions, intravenous products, controlled substances for medical administration, naloxone, and drug deactivation systems. The scope diverges from the abstract code name — state and local buyers are soliciting broad pharmaceutical supply agreements rather than a single formulation. Issuing bodies include state departments of corrections, county governments, and county community health agencies. Washington State Department of Corrections and Seminole County, Florida have posted opportunities under this code in the past four months.

Washington State Department of Corrections issued RFQ RFQQK13020 due October 7, 2026, seeking parenteral products, services, and equipment for eight correctional facilities across three regions (West, Central, and East), with an initial contract term running November 26, 2026 through June 30, 2030. DOC anticipates selecting up to three bidders per region and requires delivery of parenteral nutrition bags within 24 hours of order and other parenteral products within 8 hours, with fixed pricing for the initial two-year term; the pre-bid conference was held September 23, 2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, though the opportunity's due date of July 26, 2023, appears to reflect a historical record. Recent activity concentrates in Washington and Florida, with both opportunities structured as multi-award, term-based contracts requiring established pharmaceutical supply and delivery capability.